Koji Takagi1, Alice Blet1,2, Bruno Levy3, Benjamin Deniau1,2, Feriel Azibani1, Elodie Feliot1,2, Andreas Bergmann4, Karine Santos4, Oliver Hartmann4, Etienne Gayat1,2,5, Alexandre Mebazaa1,2,5, Antoine Kimmoun1,3. 1. Inserm UMR-S 942, Cardiovascular Markers in Stress Conditions (MASCOT), University of Paris, Paris, France. 2. Department of Anaesthesiology, Burn and Critical Care, University Hospitals Saint-Louis-Lariboisière, AP-HP, Paris, France. 3. Intensive Care Medicine Brabois, CHRU de Nancy, INSERM U1116, 54511, Vandoeuvre-les-Nancy, Université de Lorraine, Nancy, France. 4. 4TEEN4 Pharmaceuticals GmbH, Hennigsdorf, Germany. 5. Université de Paris, Paris, France.
Abstract
AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of cardiovascular mediators. Its administration has been shown to be associated with impaired cardiac contraction and kidney haemodynamics while its inhibition restored cardiac contraction in a pre-clinical model of severe heart failure in mice. Circulating DPP3 (cDPP3) was found to be elevated in shock. The present study aims to assess the association between cDPP3 and worsening haemodynamics, namely refractory shock, in a cohort of cardiogenic shock (CS). METHODS AND RESULTS: This is an ancillary study of OptimaCC, a prospective, double-blind, multicentre, randomized study assessing efficacy and safety of catecholamines in 57 patients with CS after acute myocardial infarction. cDPP3 was measured in plasma at inclusion, 24 h, 48 h, and 72 h, and haemodynamic and biological parameters were recorded at inclusion. cDPP3 values were higher in refractory CS than non-refractory CS at inclusion (median [interquartile range]; 76.1 [37.9-238.7] ng/mL vs. 32.8 [23.9-47.6] ng/mL, P = 0.014), at 24 h (P < 0.001) and up to 48 h (P = 0.027). Furthermore, cDPP3 at inclusion discriminated CS patients who did develop refractory shock vs. non-refractory with an area under the curve of 0.73 (95% confidence interval [CI] 0.55-0.92). The high cDPP3 group (cDPP3 ≥59.1 ng/mL) at inclusion had a higher Simplified Acute Physiology Score II (SAPS II), lower cardiac index and lower estimated glomerular filtration rate. More importantly, in CS patients with high cDPP3 at inclusion, those who rapidly decreased cDPP3 at 24 h exhibited a striking reduction in the occurrence of refractory shock and death. CONCLUSION: In CS patients, cDPP3 gives an early prediction of outcome, including development of refractory status and/or survival. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01367743.
RCT Entities:
AIMS: Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of cardiovascular mediators. Its administration has been shown to be associated with impaired cardiac contraction and kidney haemodynamics while its inhibition restored cardiac contraction in a pre-clinical model of severe heart failure in mice. Circulating DPP3 (cDPP3) was found to be elevated in shock. The present study aims to assess the association between cDPP3 and worsening haemodynamics, namely refractory shock, in a cohort of cardiogenic shock (CS). METHODS AND RESULTS: This is an ancillary study of OptimaCC, a prospective, double-blind, multicentre, randomized study assessing efficacy and safety of catecholamines in 57 patients with CS after acute myocardial infarction. cDPP3 was measured in plasma at inclusion, 24 h, 48 h, and 72 h, and haemodynamic and biological parameters were recorded at inclusion. cDPP3 values were higher in refractory CS than non-refractory CS at inclusion (median [interquartile range]; 76.1 [37.9-238.7] ng/mL vs. 32.8 [23.9-47.6] ng/mL, P = 0.014), at 24 h (P < 0.001) and up to 48 h (P = 0.027). Furthermore, cDPP3 at inclusion discriminated CS patients who did develop refractory shock vs. non-refractory with an area under the curve of 0.73 (95% confidence interval [CI] 0.55-0.92). The high cDPP3 group (cDPP3 ≥59.1 ng/mL) at inclusion had a higher Simplified Acute Physiology Score II (SAPS II), lower cardiac index and lower estimated glomerular filtration rate. More importantly, in CS patients with high cDPP3 at inclusion, those who rapidly decreased cDPP3 at 24 h exhibited a striking reduction in the occurrence of refractory shock and death. CONCLUSION: In CS patients, cDPP3 gives an early prediction of outcome, including development of refractory status and/or survival. CLINICAL TRIAL REGISTRATION: clinicaltrials.gov Identifier NCT01367743.
Authors: Sabri Soussi; Divya Sharma; Peter Jüni; Gerald Lebovic; Laurent Brochard; John C Marshall; Patrick R Lawler; Margaret Herridge; Niall Ferguson; Lorenzo Del Sorbo; Elodie Feliot; Alexandre Mebazaa; Erica Acton; Jason N Kennedy; Wei Xu; Etienne Gayat; Claudia C Dos Santos Journal: Crit Care Date: 2022-04-21 Impact factor: 19.334
Authors: Shalinee Jha; Ulrike Taschler; Oliver Domenig; Marko Poglitsch; Benjamin Bourgeois; Marion Pollheimer; Lisa M Pusch; Grazia Malovan; Saša Frank; Tobias Madl; Karl Gruber; Robert Zimmermann; Peter Macheroux Journal: J Biol Chem Date: 2020-06-16 Impact factor: 5.157
Authors: Eva M Boorsma; Jozine M Ter Maaten; Kevin Damman; Dirk J van Veldhuisen; Kenneth Dickstein; Stefan D Anker; Gerasimos Filippatos; Chim C Lang; Marco Metra; Karine Santos; Adriaan A Voors Journal: Eur J Heart Fail Date: 2021-03-30 Impact factor: 15.534
Authors: Mahir Karakas; Dominik Jarczak; Martin Becker; Kevin Roedl; Marylyn M Addo; Frauke Hein; Andreas Bergmann; Jens Zimmermann; Tim-Philipp Simon; Gernot Marx; Marc Lütgehetmann; Axel Nierhaus; Stefan Kluge Journal: Biomolecules Date: 2020-08-11